High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2020-10-26 / Front Oncol 2020;10:536700Emerging Immunotherapies in the Treatment of Brain Metastases
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2020-10-26 / Oncologist 2020 Oct;Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-10-14 / Nat Commun 2020 10;11(1):5173Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2020-10-01 / Anticancer Res 2020 Oct;40(10):5765-5776Evaluation of Apoptosis Induction by Newcastle Disease Virus LaSota Strain in Human Breast Carcinoma Cells
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2020-10-01 / Arch Razi Inst 2020 10;75(3):367-376
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution